X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2139) 2139
Book Review (272) 272
Publication (127) 127
Book Chapter (5) 5
Conference Proceeding (5) 5
Dissertation (3) 3
Magazine Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1912) 1912
humans (1613) 1613
aminoquinolines - administration & dosage (1097) 1097
male (1015) 1015
female (972) 972
aminoquinolines - therapeutic use (794) 794
animals (770) 770
imiquimod (663) 663
dermatology (649) 649
administration, topical (564) 564
aminoquinolines - pharmacology (515) 515
middle aged (494) 494
treatment outcome (466) 466
adult (465) 465
skin neoplasms - drug therapy (430) 430
aged (421) 421
antineoplastic agents - administration & dosage (401) 401
mice (393) 393
aminoquinolines - adverse effects (345) 345
adjuvants, immunologic - administration & dosage (335) 335
antineoplastic agents - therapeutic use (267) 267
administration, cutaneous (261) 261
adjuvants, immunologic - therapeutic use (230) 230
skin neoplasms - pathology (221) 221
care and treatment (218) 218
pharmacology & pharmacy (215) 215
aged, 80 and over (190) 190
dose-response relationship, drug (189) 189
carcinoma, basal cell - drug therapy (182) 182
rats (181) 181
cancer (171) 171
immunology (171) 171
skin (170) 170
follow-up studies (164) 164
ointments (149) 149
abridged index medicus (148) 148
drug therapy (145) 145
drug administration schedule (142) 142
analysis (139) 139
disease models, animal (139) 139
aminoquinolines (137) 137
mice, inbred c57bl (135) 135
condylomata acuminata - drug therapy (132) 132
5-percent cream (131) 131
adolescent (130) 130
research (129) 129
time factors (125) 125
therapy (124) 124
immune-response modifier (122) 122
oncology (116) 116
inflammation (114) 114
double-blind (113) 113
infectious diseases (111) 111
surgery (111) 111
topical imiquimod (108) 108
antineoplastic agents - adverse effects (106) 106
adjuvants, immunologic - adverse effects (105) 105
dosage and administration (105) 105
dendritic cells (102) 102
administration, oral (101) 101
health aspects (100) 100
aminoquinolines - chemistry (98) 98
melanoma (98) 98
psoriasis (98) 98
expression (97) 97
interferon inducers - therapeutic use (97) 97
malaria (95) 95
aminoquinolines - pharmacokinetics (94) 94
skin cancer (94) 94
double-blind method (93) 93
mice, inbred balb c (93) 93
cream (92) 92
carcinoma, basal cell - pathology (87) 87
child (86) 86
efficacy (83) 83
skin - pathology (83) 83
immunotherapy (82) 82
adjuvants, immunologic - pharmacology (80) 80
interferon inducers - administration & dosage (79) 79
basal cell carcinoma (76) 76
drug therapy, combination (76) 76
basal-cell carcinoma (75) 75
recurrence (75) 75
psoriasis - chemically induced (74) 74
prospective studies (73) 73
young adult (73) 73
apoptosis (71) 71
cytokines (71) 71
warts (71) 71
carcinoma, squamous cell - drug therapy (70) 70
toll-like receptors (70) 70
activation (68) 68
cells (68) 68
combined modality therapy (68) 68
interferon (66) 66
keratosis, actinic - drug therapy (66) 66
actinic keratosis (65) 65
antineoplastic agents - pharmacology (65) 65
biopsy (65) 65
disease (65) 65
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2026) 2026
Russian (34) 34
German (32) 32
French (18) 18
Spanish (17) 17
Japanese (4) 4
Bulgarian (3) 3
Chinese (3) 3
Hungarian (3) 3
Danish (2) 2
Italian (2) 2
Finnish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Pharmacology, ISSN 0007-1188, 07/2009, Volume 157, Issue 5, pp. 831 - 843
Background and purpose:  Buprenorphine displays attributes of opioids, but also some features distinct from them. We examined spinal and supraspinal signal... 
mechanism of action | supraspinal | buprenorphine | analgesia (antinociception) | Supraspinal | Analgesia (antinociception) | Buprenorphine | Mechanism of action | MOLECULAR REARRANGEMENTS | OKADAIC-ACID | ANTISENSE OLIGODEOXYNUCLEOTIDES | MU-OPIOID RECEPTOR | INTRINSIC EFFICACY | SERINE/THREONINE PROTEIN PHOSPHATASES | PARTIAL AGONIST | PHARMACOLOGY & PHARMACY | MORPHINE-THEBAINE GROUP | TAIL-FLICK TEST | INDUCED ANTINOCICEPTION | Fentanyl - administration & dosage | Piperazines - administration & dosage | Narcotic Antagonists - administration & dosage | Serotonin Antagonists - administration & dosage | Phosphoprotein Phosphatases - metabolism | Aminoquinolines - administration & dosage | Injections, Intraventricular | Oligonucleotides, Antisense - metabolism | Male | Opioid Peptides - administration & dosage | Pain - chemically induced | Adrenergic alpha-Antagonists - administration & dosage | Pain - metabolism | GTP-Binding Proteins - genetics | Okadaic Acid - administration & dosage | Brain - metabolism | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Benzamides - administration & dosage | Pain Threshold - drug effects | Anesthetics, Local - administration & dosage | Pertussis Toxin - administration & dosage | Receptor, Serotonin, 5-HT1A - metabolism | Disease Models, Animal | Receptors, Opioid - metabolism | Injections, Spinal | Pyridines - administration & dosage | Pain - prevention & control | Phosphoprotein Phosphatases - antagonists & inhibitors | Yohimbine - administration & dosage | Brain - drug effects | Buprenorphine - administration & dosage | Animals | Signal Transduction - drug effects | Analgesics, Opioid - administration & dosage | Acetylcholine | Mice | Naloxone - administration & dosage | Pain Measurement | Morphine - administration & dosage | Receptors, Opioid - drug effects | Serotonin 5-HT1 Receptor Antagonists | GTP-Binding Proteins - metabolism | Index Medicus | Research Papers
Journal Article
Prostate, ISSN 0270-4137, 06/2009, Volume 69, Issue 9, pp. 917 - 927
BACKGROUND. A phase I/II trial was conducted to assess feasibility and tolerability of tumor associated antigen peptide vaccination in hormone sensitive... 
Prostate carcinoma | Biochemical recurrence | Hormone sensitive | Peptide vaccination | DENDRITIC CELLS | CLINICAL-TRIAL | biochemical recurrence | hormone sensitive | RADICAL PROSTATECTOMY | PERIPHERAL-BLOOD | TUMOR-CELLS | CYTOTOXIC T-LYMPHOCYTES | peptide vaccination | MESSENGER-RNA | GM-CSF | ENDOCRINOLOGY & METABOLISM | UROLOGY & NEPHROLOGY | ANTITUMOR IMMUNITY | prostate carcinoma | ANTIGEN | Humans | Middle Aged | Aminoquinolines - administration & dosage | Drug Resistance, Neoplasm | Male | Tomography, X-Ray Computed | Secondary Prevention | Antineoplastic Agents - administration & dosage | Hormones | Prostatic Neoplasms - immunology | Antigens, Neoplasm - administration & dosage | RNA, Messenger - administration & dosage | Hyperthermia, Induced | Protamines - administration & dosage | Antigens, Neoplasm - adverse effects | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | Granulocyte-Macrophage Colony-Stimulating Factor - administration & dosage | HLA-A2 Antigen - administration & dosage | Cancer Vaccines - administration & dosage | Peptide Fragments - administration & dosage | Cancer Vaccines - adverse effects | Combined Modality Therapy | Prostate-Specific Antigen - blood | HLA-A2 Antigen - adverse effects | Mannitol - analogs & derivatives | Magnetic Resonance Imaging | Mannitol - administration & dosage | Oleic Acids - administration & dosage | Aged | Peptide Fragments - adverse effects | Mucin-1 - genetics | Index Medicus
Journal Article
Journal Article
Psychopharmacology, ISSN 0033-3158, 10/2017, Volume 234, Issue 20, pp. 3009 - 3025
Gamma-aminobutyric acid (GABA)ergic neurons of the substantia nigra pars reticulata (SNpr) are connected to the deep layers of the superior colliculus (dlSC).... 
Deep layers of the superior colliculus | Tectonigral opioid pathways | Neurosciences | Biomedicine | Nociceptin/Orphanin FQ | GABAergic nigrotectal pathways | Pharmacology/Toxicology | Psychiatry | FEAR-INDUCED ANTINOCICEPTION | PSYCHIATRY | IMMUNOHISTOCHEMICAL LOCALIZATION | PERIAQUEDUCTAL GRAY-MATTER | NEUROSCIENCES | INFERIOR COLLICULUS | SUPERIOR COLLICULUS | OPIOID RECEPTOR | ELECTRICAL-STIMULATION | DEFENSIVE BEHAVIOR | PHARMACOLOGY & PHARMACY | CENTRAL-NERVOUS-SYSTEM | Somatostatin - analogs & derivatives | Pars Reticulata - drug effects | Pars Reticulata - physiology | Rats, Wistar | Superior Colliculi - drug effects | Aminoquinolines - administration & dosage | Somatostatin - administration & dosage | Fear - drug effects | Rats | Superior Colliculi - physiology | Male | gamma-Aminobutyric Acid - administration & dosage | Opioid Peptides - administration & dosage | Fear - physiology | Dose-Response Relationship, Drug | Bicuculline - administration & dosage | Naloxone - analogs & derivatives | Receptors, Opioid - physiology | Benzamides - administration & dosage | Animals | Analgesics, Opioid - administration & dosage | Oligopeptides - administration & dosage | Naloxone - administration & dosage | GABA | Basal ganglia | Health aspects | Rattus norvegicus | Colliculus | Nociceptin receptors | Opioid receptors | γ-Aminobutyric acid A receptors | Narcotics | Endomorphin | Defensive behavior | Substantia nigra | Superior colliculus | Nociceptin | Receptors | γ-Aminobutyric acid | Microinjection | Naloxone | Pathways | Endomorphin-1 | Psychopharmacology | Receptor mechanisms | Pretreatment | Substantia nigra pars reticulata | Bicuculline | Index Medicus
Journal Article
Lancet Oncology, ISSN 1470-2045, 2013, Volume 14, Issue 7, pp. 647 - 654
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 2011, Volume 153, Issue 3, pp. 240 - 248
The aim of this study was to evaluate the ability of a low-fluence fractional erbium:yttrim-aluminum-garnet (Er:YAG) laser, with a wavelength of 2940 nm, for... 
Peptides | Imiquimod | Macromolecules | Fractional laser | Skin permeation | MOLECULAR-WEIGHT | PHOTOTHERMOLYSIS | ERBIUM-YAG LASER | CHEMISTRY, MULTIDISCIPLINARY | 5-PERCENT CREAM | HAIR-FOLLICLES | SQUAMOUS-CELL CARCINOMA | 5-AMINOLEVULINIC ACID | PHARMACOLOGY & PHARMACY | SKIN | TRANSDERMAL PEPTIDE DELIVERY | ACTINIC KERATOSIS | Drug Delivery Systems - instrumentation | Skin - metabolism | Peptides - pharmacokinetics | Aminoquinolines - administration & dosage | Administration, Cutaneous | Chromatography, High Pressure Liquid | Peptides - administration & dosage | Dextrans - pharmacokinetics | Lasers, Solid-State | Swine | Female | Skin - pathology | Macromolecular Substances - administration & dosage | Skin Absorption | Ultraviolet Rays - adverse effects | Microscopy, Confocal | Animals | Mice, Nude | Skin - radiation effects | Macromolecular Substances - pharmacokinetics | Cell Proliferation - drug effects | Mice | Aminoquinolines - pharmacokinetics | In Vitro Techniques | Dextrans - administration & dosage | Drug Delivery Systems - methods | Cell Proliferation - radiation effects | Dextran | Lasers | Analysis | Fluorescein | Dosage and administration | Biopolymers | Transdermal medication | Fluorescein isothiocyanate | U.V. radiation | Cream | Fluorescence | Confocal microscopy | Drug delivery | Molecular weight | Wavelength | imiquimod | Skin | Diffusion | Controlled release | Index Medicus
Journal Article
Malaria Journal, ISSN 1475-2875, 2011, Volume 10, Issue 1, pp. 212 - 212
Background: Tafenoquine is an 8-aminoquinoline being developed for radical cure (blood and liver stage elimination) of Plasmodium vivax. During monotherapy... 
VIVAX MALARIA | RELAPSE | ANTIMALARIAL-DRUGS | WR-238605 | FALCIPARUM-MALARIA | PHARMACOKINETICS | CHLOROQUINE | PRIMAQUINE | PARASITOLOGY | TROPICAL MEDICINE | BLOOD | Quinine - pharmacokinetics | Artemisinins - pharmacokinetics | Humans | Aminoquinolines - administration & dosage | Male | Ethanolamines - administration & dosage | Ethanolamines - pharmacokinetics | Mass Spectrometry | Mefloquine - administration & dosage | Mefloquine - pharmacokinetics | Chromatography, Liquid | Fluorenes - administration & dosage | Plasmodium cynomolgi | Disease Models, Animal | Fluorenes - pharmacokinetics | Antimalarials - pharmacokinetics | Artemisinins - administration & dosage | Treatment Outcome | Macaca mulatta - parasitology | Drug Therapy, Combination - methods | Animals | Antimalarials - administration & dosage | Plasma - chemistry | Primate Diseases - drug therapy | Quinine - administration & dosage | Chloroquine - administration & dosage | Aminoquinolines - pharmacokinetics | Malaria - drug therapy | Chloroquine - pharmacokinetics | Drug Combinations | Tafenoquine | Complications and side effects | Plasmodium | Malaria | Causes of | Physiological aspects | Dosage and administration | Research | Drug therapy | Drugs | Phosphates | Mefloquine | Toxicity | Liver | Chloroquine | Cohorts | Parasites | Monkeys & apes | Quinine | Blood | Fever | Glucose dehydrogenase | Armed forces | Artemether | Laboratory animals | Glucosephosphate dehydrogenase | Drug dosages | Public health | Index Medicus
Journal Article
Journal Article
Dermatology (Actas Dermo-Sifiliográficas, English Edition), ISSN 1578-2190, 2016, Volume 107, Issue 9, pp. 730 - 739
Graphical abstract 
Dermatology | Internal Medicine | 5-Fluorouracil | Cáncer cutáneo | Imiquimod | Diclofenaco | 5-Fluorouracilo | Skin cancer | Diclofenac | Ingenol | Diclofenac - pharmacology | Meta-Analysis as Topic | Adjuvants, Immunologic - administration & dosage | Adjuvants, Immunologic - pharmacology | Skin Neoplasms - drug therapy | Neoplastic Stem Cells - drug effects | Dermatologic Agents - administration & dosage | Humans | Neoplasm Proteins - physiology | Aminoquinolines - administration & dosage | Antineoplastic Agents - therapeutic use | Dermatologic Agents - therapeutic use | Administration, Cutaneous | Antineoplastic Agents - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Antimetabolites, Antineoplastic - administration & dosage | Fluorouracil - therapeutic use | Fluorouracil - administration & dosage | Diterpenes - administration & dosage | Antimetabolites, Antineoplastic - pharmacology | Antineoplastic Agents - pharmacology | Adjuvants, Immunologic - therapeutic use | Aminoquinolines - pharmacology | Dermatologic Agents - pharmacology | Carcinoma - drug therapy | Diterpenes - pharmacology | Diclofenac - therapeutic use | Diterpenes - therapeutic use | Skin Neoplasms - immunology | Carcinoma - immunology | Antigen-Presenting Cells - drug effects | Clinical Trials as Topic | Skin Neoplasms - metabolism | Antimetabolites, Antineoplastic - therapeutic use | Drug Resistance, Neoplasm - genetics | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Fluorouracil - pharmacology | Carcinoma - metabolism | Diclofenac - administration & dosage | Aminoquinolines - therapeutic use | Drug Resistance, Neoplasm - physiology
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 11/2014, Volume 59, Issue 9, pp. 1246 - 1255
Journal Article